Press Release June 10, 2022

Senti Bio Debuts as Publicly Traded Company

The Life Sciences and SPAC teams advised Senti Biosciences on its previously announced business combination with Dynamics Special Purpose Corp. (Nasdaq: DYNS), a special purpose acquisition company. Senti Biosciences, Inc., the resulting combined company, commenced trading on the Nasdaq Global Market under the symbol “SNTI” on June 9, 2022.

Senti Bio's mission is to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. To accomplish this, Senti Bio is building a synthetic biology platform that may enable the company to program next-generation cell and gene therapies with what it refers to as “gene circuits.”  

The Goodwin team was led by Jocelyn Arel, Maggie Wong, Mike Patrone, Alicia Tschirhart, Wei Xu, Elena Hera, Jesse Fishman, Amanda Schwarzenbart, Sara Lepis, Adanna Uwazruike, Lucy Dempsey and Sean Cheatle (Corporate); Todd Pollack and Gregg Couglin (Tax); Matthew Wetzel and Anne Brendel (Healthcare Regulatory); Michael Shuster and Kevin Kabler (IP); Sarah Bock, Morgan Frisoli, and Rahat Tariq (Benefits); Brian Muhkerjee (Insurance); Bradford Smith (Employment); Kara Kuritz and Ortal Ben Aharon (Antitrust); Julie Tibbets, Steven Tjoe and Emily Tribulski (FDA); Jacqueline Klosek, Jonathan Newmark and Brian Schumer (Privacy); and Morgan Mordecai and Jennifer Luz (Litigation); with invaluable support from Tricia Hojo and Nathan Needle (Paralegal).

For more details, read the press release and article in Endpoints News.